Together, these data indicate that mutations such as R172H in murine Trp53 and R248W in human TP53 function as GOF mutations to drive prostate tumorigenesis in mice and growth of human PCa cells in culture, respectively. This evidence concerns the gene TP53 and urogenital neoplasm.